Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452669 · ClinicalTrials.gov registry record · Phase 2
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
A Phase 2 study, sponsored by Aerogen Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04452669: Completed Phase 2 study, sponsored by Aerogen Pharma Limited.
NCT04452669 is a Phase 2 study that has completed, run by Aerogen Pharma Limited. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452669, a Phase 2 study, has completed, sponsored by Aerogen Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Primary Outcome
Number of participants that were extubated
Interventions
- DRUG VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
What the finished NCT04452669 record still lists
NCT04452669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) is the first listed.
NCT04452669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04452669 about?
NCT04452669 is a clinical study titled "VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation". The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
What is the current status of trial NCT04452669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-09-15. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT04452669?
The interventions under investigation include: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (DRUG).
Who is sponsoring clinical trial NCT04452669?
This trial is sponsored by Aerogen Pharma Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04452669's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI